Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viking Therapeutics, Inc.

http://www.vikingtherapeutics.com/

Latest From Viking Therapeutics, Inc.

Boehringer Backs Up Best-In-Class MASH Claims With Fibrosis Data

Survodutide burnishes its best-in-class MASH case with a 64% improvement in moderate-to advanced fibrosis at Phase II, but tolerability an issue

Clinical Trials Metabolic Disorders

EASL: Tirzepatide Is The One To Beat In MASH

An important mid-stage trial succeeds, but an odd finding on the fibrosis endpoint will spur close examination of Lilly’s incretin.

Clinical Trials Metabolic Disorders

Viking Bolsters MASH Case With 52-Week Histology Data

Viking will look to plan a Phase III program with the FDA after showing 52-week success on MASH resolution and fibrosis reduction with VK2809. The firm still hopes to move forward with a partner.

Clinical Trials Business Strategies

Roche’s New Obesity Play Shows Early Promise

CT-388 hits in Phase I, but there is a long way to go before the Carmot acquisition pays off.

Clinical Trials Metabolic Disorders
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register